News
PDSB Stock Hits 37-Week High " Here's The Latest On Its Therapy To Treat Metastatic Colorectal Cancer
1+ day, 21+ min ago (274+ words) Shares of PDS Biotechnology (PDSB) surged 24% on Wednesday to hit their highest levels since Aug. 27, 2025, after the biotech firm reported promising Phase 2 trial results for its therapy to treat metastatic colorectal cancer. PDSB stock recorded its biggest intraday gains since…...
REPL Stock Dives After FDA Refuses Approval For Skin Cancer Drug
6+ day, 5+ hour ago (192+ words) Shares of Replimune Group Inc. (REPL) slumped 19% on Friday after the U. S. Food and Drug Administration refused approval for the company's melanoma drug RP1. The agency said in a letter to the company that the data submitted by Replimune as part of…...
REPL Vs IOVA: FDA Decision Day Could Test Biotech Bulls" Conviction On These Melanoma Plays
6+ day, 9+ hour ago (579+ words) Shares of Replimune Group, Inc. (REPL) and Iovance Biotherapeutics, Inc. (IOVA) are back in focus on Friday ahead of an FDA decision on the former's lead immunotherapy candidate RP1, as investors compare a near-term approval catalyst with an already approved melanoma…...
TLX Stock Surges Overnight After FDA Agrees To Review Brain Cancer Imaging Agent Application
6+ day, 14+ hour ago (435+ words) U. S. -listed shares of Telix Pharmaceuticals rose'nearly 9% overnight heading into Friday'after the FDA accepted a New Drug Application(NDA) for its TLX101-Px1, a brain cancer imaging agent.' The'Australian company said the approval was given for the resubmission of its application,'sending shares…...
Novo Nordisk's Wegovy Gets A Logistics Boost " EU Eases Shipping Rules
1+ week, 3+ hour ago (293+ words) Novo Nordisk (NVO) on Thursday announced that the European Medicines Agency approved flexible delivery conditions for its blockbuster Wegovy injection, allowing transport at up to 30 C for up to 48 hours, potentially easing supply chain constraints for GLP-1 treatments. NVO shares…...
REPL Stock On Track For Worst Drop In Nearly 7 Months Ahead Of FDA Decision On Skin Cancer Drug
1+ week, 1+ day ago (281+ words) Shares of Replimune Group Inc (REPL) fell 15% on Wednesday as the deadline for the U. S. Food and Drug Administration's decision on its skin cancer therapy RP1 draws close. If losses hold, REPL is on track for its worst session in nearly seven…...
REPL Stock Rallies In Anticipation Of FDA Decision On Skin Cancer Drug
2+ week, 2+ hour ago (280+ words) Shares of Replimune Group Inc (REPL) closed 11% higher on Thursday as the deadline for the U. S. Food and Drug Administration's decision on its skin cancer therapy RP1 draws close. The FDA is slated to decide on the company's application for RP1 in the…...
GLP-1 Rivalry Heats Up: Novo Nordisk Claims Lead Over Lilly's Newly Approved Pill
2+ week, 21+ hour ago (134+ words) Novo Nordisk (NVO) on Thursday said that oral semaglutide 25 mg delivered greater weight loss than orforglipron, just a day after the U. S. Food and Drug Administration approved Eli Lilly's weight loss drug. Results from the ORION study showed semaglutide led to…...
Why Is BEAM Stock Edging Higher After Hours Today?
2+ week, 17+ hour ago (231+ words) Shares of Beam Therapeutics (BEAM) rallied 3% after hours on Wednesday after the company said that its clinical trial evaluating ristoglogene autogetemcel for the treatment of sickle cell disease (SCD) with severe vaso-occlusive crises demonstrated encouraging efficacy. The company said that…...
ANRO Stock Falls After Hours On Failed Schizophrenia Study Results
2+ week, 1+ day ago (220+ words) Shares of Alto Neuroscience, Inc. (ANRO) fell as much as 10% after hours on Wednesday after the company said that its experimental drug for the treatment of schizophrenia failed to achieve statistical significance on key goals in a mid-stage study. The…...